Alligator Bioscience
June 16, 2025
Company Presentation
Oncology
154
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
Company HQ City:
Lund
Company HQ State:
Skåne Len
Company HQ Country:
Sweden
Year Founded:
2001
Lead Product in Development:
mitazalimab
CEO
Søren Bregenholt
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
Exchange
NASDAQ Stockholm
Ticker
ATORX
When you expect your next catalyst update?
mitazalimab license or acquisition
What is your next catalyst (value inflection) update?
H2 2025
Website
https://alligatorbioscience.se/en/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}